You Got the Cells Now Where Do They Go After Stem Cell Delivery

The moment cells enter the body, the story becomes physical. They meet rushing blood, narrow capillaries, sticky vessel walls, immune sentinels, damaged tissue, healthy tissue, low oxygen, mechanical pressure, and biochemical signals they may or may not be able to read.

That is why the question “Where do the cells go?” has no single answer. It depends on the cell type, how the cells were prepared, the route of administration, the species being studied, the disease model, and the method used to track them.

Researchers have learned a lot from animal studies, imaging work, tissue sampling, and clinical investigations. They have also learned where the evidence is thinner than the marketing often suggests. One key point deserves to be stated early: cells do not automatically travel to wherever the body is injured. Some cell migration has been demonstrated in specific settings, but broad claims about perfect injury-seeking behavior go beyond the evidence.

This article is informational only and does not offer medical advice or treatment recommendations.

Once cells enter the body, route and anatomy shape where they are likely to appear first.

The route of administration sets the first scene

Cell biodistribution means the pattern of where administered cells are found over time. The first few minutes are often shaped less by “homing” and more by anatomy.

A cell given into a vein enters the bloodstream and quickly reaches the lungs. A cell injected into a joint starts in the joint space. A cell placed into muscle must survive in muscle tissue. A cell delivered near the spinal canal faces a different fluid environment altogether.

That first location matters because cells are not like small-molecule drugs. Many therapeutic cell products are relatively large, living units. Mesenchymal stromal cells, often called MSCs, are much bigger than many blood cells. They can be flexible, but they still encounter tight passages, shear stress, and immune surveillance.

Researchers generally think about biodistribution in phases:

• Initial distribution

  Where the cells physically go right after delivery.

  
  

• Retention

  How many remain near the first site or in the first organs they encounter.

  
  

• Survival

  How long detectable cells remain alive and functional.

  
  

• Redistribution or clearance

  Whether cells move elsewhere, die, are broken down, or are cleared by immune and filtering organs.

  
  

• Biological effect

  Whether cells act through direct engraftment, secreted signals, immune modulation, or other mechanisms.

  
  

These phases do not always line up neatly. A cell may be detectable but no longer viable. A cell may die quickly but still release signals or trigger immune responses. A treatment effect, when seen in research, does not always mean large numbers of cells permanently settled into the target tissue.

IV administration often sends cells to the lungs first

Intravenous delivery is appealing because it is simple compared with many local procedures. Cells enter a vein, join the circulation, and travel through the body. But the first major capillary bed they meet is usually in the lungs.

That creates the well-known pulmonary first-pass effect.

After IV administration, many large administered cells become trapped or temporarily retained in the narrow blood vessels of the lungs. This has been demonstrated in many preclinical studies using labeled cells and imaging methods. The effect is especially relevant for larger adherent cells such as MSCs.

The lung is not a passive filter in this story. It has a dense web of capillaries designed for gas exchange. Blood cells squeeze through this network constantly. Larger infused cells can slow down, lodge, interact with vessel walls, or become cleared.

What happens next varies.

Some studies show that lung signal decreases over time, while signal may later appear in organs involved in clearance, such as the liver and spleen. In some models, small numbers of cells or cell-derived material may be detected elsewhere. The exact pattern depends on the cell type, dose, cell size, surface markers, viability, and study method.

A useful way to frame the evidence is this:

What has been demonstrated	What should be treated carefully
IV cells often show strong early lung retention, especially larger cell types.	The idea that IV cells reliably pass through the lungs and travel in large numbers to any injured site.
Labeled cell signal may later appear in liver, spleen, kidneys, or other clearance-related tissues.	The assumption that labeled signal always means living therapeutic cells are present.
Some cells can interact with immune cells and vascular tissues after IV delivery.	Claims that long-term engraftment throughout the body is a routine outcome.

This does not mean IV delivery is useless. Some cell therapies may aim to influence immune responses or inflammation through systemic interactions. In that case, the lungs, blood, spleen, liver, and immune system may all be part of the mechanism. But the route does not guarantee that intact living cells will gather at an injury site in large numbers.

The pulmonary first-pass effect is largely about anatomy, size, and blood flow.

Local injection keeps the story closer to the target, but not perfectly

Local injection changes the starting point. Instead of entering the bloodstream first, cells are placed directly into or near the tissue of interest. Examples include injection into a joint, tendon, muscle, heart tissue, skin wound, or other local site in research or clinical contexts.

This route can increase early cell presence at the target area compared with IV delivery. That finding makes intuitive sense. If cells are placed inside a joint, more of them are likely to be found there at first than if they were infused into a vein.

But local injection is not the same as perfect retention.

Cells may:

• Leak out through the needle track

• Disperse into nearby tissue planes

• Enter lymphatic or blood vessels

• Die from low oxygen, inflammation, or mechanical stress

• Be cleared by immune cells

• Remain near the injection site without integrating into the tissue

  
  

In musculoskeletal research, for instance, locally injected cells may be found near the injection site early on, but long-term survival and stable engraftment are often limited. In heart research, cells injected into damaged heart muscle may show poor long-term retention, partly because the heart is constantly moving and has a challenging oxygen and inflammatory environment.

Local injection also creates a different safety profile. A dense cluster of cells in a confined space may behave differently than cells spread through circulation. Placement, dose, tissue type, and product characteristics matter.

The demonstrated finding is straightforward: local delivery can increase early local exposure. The hypothesis, still tested in different ways, is that longer exposure near injured tissue may improve signaling, repair responses, or immune modulation. That does not mean the cells become replacement tissue by default.

Cell survival is often shorter than people imagine

Many people picture administered stem cells as tiny repair workers that settle in, build new tissue, and stay for years. In many research settings, that picture does not match what investigators see.

Cell survival after delivery is often limited. Cells can face harsh conditions almost immediately:

• Mechanical stress

  Infusion, injection, and passage through small vessels can damage cells.

  
  

• Low oxygen

  Injured tissues may have poor blood supply.

  
  

• Inflammation

  The same immune activity involved in injury can also attack or stress introduced cells.

  
  

• Lack of attachment

  Some cells need contact with surrounding matrix to survive well.

  
  

• Immune recognition

  Allogeneic cells, which come from a donor, may be recognized and cleared.

  
  

Tracking survival is not simple. A fluorescent dye may remain after a cell dies. A radioactive label may show where cell material went, not where living cells are working. Genetic labels can be more specific in animal studies, but they are not always practical or appropriate in humans.

So when a paper reports “cell signal” in a tissue, the next question is what kind of signal. Does it mean viable cells? Dead cell fragments? Label transferred to immune cells? Free label taken up by clearance organs?

Good biodistribution research tries to separate these possibilities, but no method is perfect.

Homing is real in some settings, but it is not a magic address system

Homing describes the ability of cells to move toward certain signals, often chemical gradients released by tissues. Immune cells do this naturally. Blood-forming stem cells can home to bone marrow after transplantation, a process with decades of clinical relevance.

For many other cell types used in regenerative medicine research, homing is more complicated.

Some administered cells express receptors that can respond to inflammatory or injury-related signals. Some studies show migration toward certain chemokines in lab dishes or animal models. Some injury models show greater cell signal near damaged tissue than healthy tissue under specific conditions.

Those are demonstrated findings in defined systems.

The leap comes when people turn those findings into a universal claim: “The cells know where to go.” That phrase is too simple. Cells may respond to certain signals, but only if they survive, reach the relevant circulation, avoid being trapped elsewhere, express the right receptors, and encounter a usable gradient. Even then, the number of cells that arrive may be small.

A better description is this: some cells may show directed migration under certain biological conditions, but biodistribution is also strongly shaped by delivery route, anatomy, cell size, immune clearance, and tissue environment.

That is less catchy, but much closer to the evidence.

Homing research often studies how cells respond to chemical gradients, not a built-in map of the body.

Paracrine signaling may explain effects without long-term engraftment

If many administered cells do not survive long term, how could they still have biological effects in some studies?

One leading explanation is paracrine signaling. This means cells release substances that influence nearby or distant cells without permanently becoming part of the tissue.

These signals may include:

• Cytokines

• Growth factors

• Lipids

• Extracellular vesicles

• RNA-containing particles

• Other cell-secreted molecules

  
  

In this model, the administered cells act less like bricks in a wall and more like temporary biochemical signal sources. They may encourage blood vessel formation, alter immune activity, reduce certain inflammatory pathways, or affect resident cells already present in the tissue.

This idea has support from many laboratory and animal studies. Conditioned media, which is fluid collected from cell cultures, can sometimes reproduce parts of the cell effect in experimental systems. Extracellular vesicles are also being studied because they may carry some of the messages cells release.

Still, paracrine signaling should not become a catch-all explanation for every claimed benefit. Researchers still need to show which signals matter, where they act, how long they persist, and whether they produce meaningful outcomes in humans.

The paracrine model does help explain a puzzle: a short cell survival window may still coincide with measurable biological changes. It also means biodistribution is not only about where intact cells go. It is also about where their signals, fragments, vesicles, and immune interactions occur.

How researchers track where cells go

Biodistribution studies use several tools, each with tradeoffs. No single method answers every question.

Tracking method	What it can show	Main limitation
Fluorescent labeling	Cell location in tissues or small animal imaging	Signal can remain after cell death or transfer to other cells
Radioactive labeling	Whole-body distribution over time	May not prove cells are alive
MRI labels	Anatomical location in some settings	Label can persist after cells die
Genetic markers in animal studies	More specific detection of donor cells	Not always applicable to humans
Tissue sampling	Direct organ-level evidence	Limited by sampling time and location

The strongest studies often combine methods. For example, imaging may show whole-body patterns, while tissue analysis checks whether the signal represents living cells, dead cells, or label uptake by other cells.

Researchers also look at function. If cells are found in the lung after IV delivery, what are they doing there? Are they lodging passively? Interacting with immune cells? Releasing vesicles? Dying and being cleared? Different studies may support different answers depending on the model.

The clearest takeaways so far

The evidence around cell biodistribution is detailed, imperfect, and still evolving. But several practical conclusions are well supported.

Route matters. IV delivery often produces early lung retention. Local injection usually increases early exposure near the target site, but retention is still incomplete.

Presence is not the same as survival. A tracking signal does not always mean living cells remain active in that tissue.

Homing is conditional. Some cells can respond to injury-related signals in specific settings, but they do not automatically travel to every damaged area.

Long-term engraftment is often limited. Many investigated cell products appear to act through temporary signaling, immune interaction, or effects on local cells rather than permanent rebuilding.

Paracrine effects are a major research focus. Secreted factors and extracellular vesicles may help explain why short-lived cells can still influence biological processes in some models.

Biodistribution research connects the delivery route with what can later be measured in tissues.

A better way to ask where the cells go

A more precise question is not only “Where do the cells go?” It is a chain of questions.

Where do they go first? How many remain there? How many survive? What tissues show signal later? Does that signal represent living cells? Do the cells engraft, interact, signal, or get cleared? Are observed effects caused by the cells themselves, by what they secrete, or by the body’s response to them?

That chain is what makes stem cell delivery scientifically interesting and clinically complex. The body is not a blank map waiting for cells to choose the injured landmark. It is a moving system of filters, signals, barriers, fluids, and immune decisions.

The most accurate picture is also the most useful one: cells follow biology, not slogans. Their journey depends on route, anatomy, survival, and context. Understanding that journey is essential for judging what any cell-based therapy can realistically do.